HYTN Innovations Expands GMP Capabilities
HYTN Innovations Inc. (CSE: HYTN, FSE: 85W0, OTC PINK: HYTNF) proudly reports an enhancement in its operational capabilities by acquiring an additional Good Manufacturing Practices (GMP) certification for its manufacturing facility in Kelowna. This new certification permits the company to undertake distribution as a licensed activity under its Drug Establishment Licence issued by Health Canada.
Benefits of the New GMP License
This recent approval complements HYTN's existing GMP certification granted under the International Pharmaceutical Co-operation Scheme (PIC/S), allowing the company to fabricate, package, and label non-sterile pharmaceutical products. With this new distribution license, HYTN can now directly distribute these GMP-certified products, although regional partnerships with distributors will still be an option based on market requirements.
Insights from Company Leadership
Jason Broome, HYTN's Chief Operations Officer, emphasized, “This license amendment is a testament to our facility's compliance and the integrity of our quality systems. It enhances our strategic expansion into non-sterile pharmaceutical production, enabling distribution in markets where it is needed.” This development not only strengthens the company’s operational framework but also positions HYTN favorably for future market opportunities.
Implications for the Market
The significance of GMP certification cannot be overstated, especially when it comes to non-sterile pharmaceuticals, including cannabis-derived products. Markets in regions such as Germany, the UK, Australia, and Poland require such certifications to ensure product safety and regulatory compliance. With the acquisition of this license, HYTN is better equipped to navigate these complex international landscapes.
Company's Vision and Growth Strategy
HYTN Innovations Inc. is dedicated to becoming a premier provider of psychoactive and psychotropic products. The company focuses on effectively identifying market opportunities and pushing innovative products through its advanced development platform. As it moves forward, HYTN aims to leverage its GMP certifications to penetrate new markets and enhance its product offerings.
Navigating GMP Guidelines
Good Manufacturing Practices (GMP) serve as essential guidelines for the manufacturing, testing, and quality assurance processes, ensuring that products are safe for consumption. These procedures are mandated by various countries to regulate manufacturers in alignment with legal standards.
Understanding PIC/S
The Pharmaceutical Inspection Co-operation Scheme (PIC/S) aims to harmonize GMP standards among its member countries, ensuring the quality and safety of medicines for both human and veterinary use. Established to streamline international pharmaceutical trading, PIC/S plays a crucial role in standardizing regulations and facilitating mutual recognition of inspection outcomes.
Company Communications
For further inquiries about HYTN Innovations, interested parties can contact:
Elliot McKerr
Chief Executive Officer
1.866.590.9289
HYTN Investor Relations:
1.866.590.9289
investments@hytn.life
Frequently Asked Questions
What is the latest GMP certification for HYTN?
HYTN Innovations has received a new GMP certification allowing it to distribute licensed products directly from its Kelowna facility.
Why is GMP certification important for HYTN?
GMP certification ensures that HYTN's products meet safety and quality standards required for distribution in several international markets.
What type of products does HYTN focus on?
HYTN specializes in psychoactive and psychotropic compounds, including cannabis-related products and psilocybin.
How does the new license affect HYTN's operations?
The new license enhances HYTN's operational capabilities, allowing direct distribution and positioning the company favorably in competitive markets.
Who can be contacted for more information regarding HYTN?
For inquiries, interested individuals can reach out to Elliot McKerr, HYTN's CEO at 1.866.590.9289.
